Treatment-Resistant Hypertension Market Summary
The Treatment-Resistant Hypertension market size in the 7MM was valued at approximately USD 6,958 million in 2025, and it is projected to reach USD 12,081 million by 2034, growing at a CAGR of 6.30% during the forecast period 2025–2034. The US had the largest market size for Treatment-Resistant Hypertension in 2024, at nearly USD 6,210 million, compared to the EU4 (Germany, France, Italy, and Spain), the UK, and Japan. Among all therapies, Calcium Channel Blockers (CCBs) accounted for the largest market size in 2024, at approximately USD 2,110 million.
Explore DelveInsight’s Full Coverage on the Treatment-Resistant Hypertension Market
Treatment-Resistant Hypertension Overview
Resistant hypertension is defined as either uncontrolled blood pressure remaining at ≥130 mmHg systolic and ≥80 mmHg diastolic despite the concurrent prescription of three or four antihypertensive drugs of different classes, or controlled blood pressure requiring four or more antihypertensive drugs, with both definitions including a thiazide diuretic at maximally tolerated doses. Blood pressure is determined by complex interactions among the Renin–Angiotensin–Aldosterone System (RAAS), the Sympathetic Nervous System (SNS), the endothelin system, natriuretic peptides, the arterial vasculature, and the immune system. Hypertension may result from dysfunction in any or all of these systems, with contributions from genetics and environmental factors such as high sodium intake, low potassium intake, sleep apnea, excessive alcohol intake, physical inactivity, and stress.
Hypertension often has no symptoms, making regular blood pressure checks essential. When extremely high (180/120 mmHg or more), it can cause headaches, chest pain, dizziness, vision changes, shortness of breath, nausea, anxiety, nosebleeds, and irregular heartbeat. If untreated, it can lead to serious conditions such as heart disease, stroke, and kidney damage.
Treatment-Resistant Hypertension Diagnosis and Treatment Algorithm
Evaluation of resistant hypertension begins with accurate blood pressure measurements, as improper techniques – such as the wrong cuff size or incorrect arm positioning – can result in falsely elevated readings. It is also crucial to rule out the white coat effect using ambulatory or home blood pressure monitoring. Automated Office Blood Pressure (AOBP) measurement, using a specialized oscillometric device to take repeated readings every 1–2 minutes while the patient sits alone in a quiet room, helps minimize this effect; a meta-analysis found AOBP results comparable to home monitoring, and Hypertension Canada Guidelines recommend it as the preferred office measurement method. True resistant hypertension can only be diagnosed once patients are confirmed to be taking their prescribed medications correctly.
Resistant hypertension is initially managed with an ACE inhibitor or ARB, a CCB, and a long-acting thiazide diuretic; if uncontrolled, spironolactone is recommended as a fourth-line agent, with ß-blockers or a-blockers added if further escalation is needed. Nonpharmacological management focuses on foundational lifestyle modifications, including smoking cessation, stress reduction, limiting alcohol intake, regular physical activity, and dietary adjustments such as the DASH diet. Further options, such as renal artery denervation, may be considered in selected cases, and patients with resistant hypertension should be referred to a hypertension specialist or a specialized hypertension center where necessary.
Treatment-Resistant Hypertension Market Players
Treatment-Resistant Hypertension companies include:
- AstraZeneca
- Mineralys Therapeutics
- E-Star BioTech
- Ionis Pharmaceuticals
- Kardiga
- Regeneron Pharmaceuticals
- Alnylam Pharmaceuticals
- Roche
- Idorsia Pharmaceutical
- Novartis
- F. Hoffmann-La Roche
- AstraZeneca (Alexion Pharmaceuticals)
- Vertex Pharmaceuticals
- Otsuka Pharmaceutical
- Biogen
- Arrowhead Pharmaceuticals
- NovelMed
- Q32 Bio
- Walden Biosciences
- Takeda Pharmaceutical
- Vera Therapeutics
- And Others
Treatment-Resistant Hypertension Epidemiology
The epidemiology section of the Treatment-Resistant Hypertension market insight report provides historical and projected patient population data across the seven major markets (7MM), segmented by total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, and age-specific diagnosed prevalent cases.
Key Findings:
- There were nearly 13,193,000 diagnosed prevalent cases of Treatment-Resistant Hypertension in the 7MM in 2024, with the US accounting for the highest number of diagnosed prevalent cases
- In 2024, the total diagnosed prevalent cases of Treatment-Resistant Hypertension in the United States were approximately 7,365,300 cases, projected to increase during the forecast period (2025–2034)
- In Japan, among the gender-specific diagnosed prevalent cases, females had a slightly higher contribution, at nearly 55% in 2024, likely to increase by 2034
- In the US in 2024, the highest diagnosed prevalence was observed in adults aged ≥60 years, with nearly 2,732,600 cases, while the lowest was in the 18–39 age group
Treatment-Resistant Hypertension Market Outlook
The Treatment-Resistant Hypertension market trends point to continued expansion through the forecast period (2025–2034), driven by rising prevalence, technological advancements, and a growing pipeline of novel therapeutics. Resistant hypertension causes vascular damage, raising the risk of cardiovascular events; older (≥65 years), obese patients with comorbidities such as diabetes, Chronic Kidney Disease, or left ventricular hypertrophy face greater difficulty in blood pressure control. Resistant hypertension is linked to higher rates of diabetes (48% vs. 30%), CKD (45% vs. 24%), ischemic heart disease (41% vs. 22%), and stroke (16% vs. 9%) compared to those with controlled blood pressure.
Management relies on lifestyle measures, pharmacotherapy, and interventional approaches where required. Pharmacotherapy includes a combination of a renin–angiotensin system blocker, a long-acting calcium channel blocker, and a diuretic at maximally tolerated doses, ideally as a single pill combination, with spironolactone recommended as the preferred fourth-line therapy. If BP control cannot be achieved, interventional approaches such as renal denervation and novel therapeutic agents should be considered. A recent meta-analysis showed lifestyle interventions as the most effective non-drug approach, lowering office SBP by -7.26 mmHg, with the DASH and Mediterranean diets both proving effective. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist (nsMRA), offers a promising alternative, blocking aldosterone effects even without its presence, since spironolactone’s anti-androgenic side effects make it less suitable for males.
Among all therapies, the Treatment-Resistant Hypertension market size in the 7MM was valued at nearly USD 6,958 million in 2025 and is anticipated to grow at a CAGR of 6.30% through 2034. Among the EU4 and the UK, Germany held the highest market share in 2024, while the UK accounted for the lowest; in Japan, the market accounted for nearly USD 259 million in 2024, expected to grow at a significant CAGR through the forecast period.
Treatment-Resistant Hypertension Marketed Drug
TRYVIO/JERAYGO (aprocitentan) – Idorsia Pharmaceutical
TRYVIO/JERAYGO is a once-daily, orally active, dual endothelin receptor antagonist that inhibits the binding of Endothelin-1 (ET-1) to ETA and ETB receptors. It represents the first new class of antihypertensive medication in over 40 years and has a low potential for drug-drug interaction, making it well suited for adult patients whose hypertension is not adequately controlled by other drugs.
- Approved by the FDA and EMA in 2024 for use in combination with other antihypertensive agents
- Commercially launched in the US in October 2024
- The MHRA approved it in January 2025 for adults whose blood pressure remains uncontrolled despite at least three other medications
- The FDA fully released TRYVIO from its Risk Evaluation and Mitigation Strategy (REMS) requirement in March 2025, reflecting improved safety data and enabling broader clinical adoption
Emerging Treatment-Resistant Hypertension Drugs
The Treatment-Resistant Hypertension market is expected to evolve significantly, supported by an active pipeline of emerging therapies addressing substantial unmet need, including baxdrostat, lorundrostat, MANP, tonlamarsen, REGN5381, and zilebesiran.
Baxdrostat (CIN-107) – AstraZeneca
Baxdrostat is a highly selective, oral small-molecule inhibitor of aldosterone synthase, in development for populations with significant unmet need, including Treatment-Resistant Hypertension, primary aldosteronism, and CKD. It selectively targets aldosterone synthase (encoded by CYP11B2) with much lower affinity for 11ß-hydroxylase (encoded by CYP11B1), the enzyme responsible for cortisol synthesis. The first Phase III data for the BaxHTN study were anticipated in the second half of 2025.
Lorundrostat (MLS-101) – Mineralys Therapeutics
Lorundrostat is a novel, oral, once-daily aldosterone synthase inhibitor with 374-fold selectivity for inhibiting aldosterone synthesis over cortisol synthesis. Mineralys Therapeutics has indicated plans to provide additional data from the pivotal Phase III Launch-HTN trial at an upcoming medical conference and in a peer-reviewed publication.
MANP – E-Star BioTech
MANP is a Guanylyl Cyclase A (GC-A) receptor activator administered subcutaneously, currently in Phase II development for participants with difficult-to-control/resistant hypertension.
Tonlamarsen (ION904) – Ionis Pharmaceuticals and Kardiga
Tonlamarsen is a subcutaneously administered therapy targeting angiotensinogen, currently in Phase II development for participants with uncontrolled hypertension.
REGN5381 – Regeneron Pharmaceuticals
REGN5381 is a Natriuretic Peptide Receptor 1 (NPR1) agonist administered via IV infusion, currently in Phase II development for participants with uncontrolled hypertension.
Zilebesiran (ALN-AGT01) – Alnylam Pharmaceuticals and Roche
Zilebesiran is a subcutaneously administered angiotensinogen expression inhibitor, currently in Phase II development for adult patients with high cardiovascular risk and hypertension not adequately controlled by standard-of-care antihypertensive medications.
Development has not been without setbacks: firibastat (Quantum Genomics) failed its Phase III trial and was discontinued due to efficacy and financial issues; VELTASSA (patiromer) saw no progress post-Phase II and was removed from development; and ocedurenone (Novo Nordisk) was terminated in Phase III after not meeting its primary endpoint.
Treatment-Resistant Hypertension Drugs Uptake
This section examines the sales uptake of potential Treatment-Resistant Hypertension drugs anticipated to launch during the study period, estimating market penetration across countries and evaluating their impact within and across therapeutic classes. Emerging therapies are analyzed on the basis of safety and efficacy in randomized clinical trials, order of market entry, broader market dynamics, and the degree to which they address unmet need. Baxdrostat, currently in Phase III with results expected in the second half of 2025, has shown significant reductions in systolic blood pressure and a favorable safety profile, outperforming TRYVIO in Phase II, positioning it as a potential blockbuster for AstraZeneca. Lorundrostat, with promising Phase II and III trial results (Advance-HTN and Launch-HTN), has shown better BP reduction than TRYVIO, positioning it as a potential best-in-class treatment.
Download the Treatment-Resistant Hypertension Market Report for In-Depth Insights on Pipeline and Forecast
Conclusion
The Treatment-Resistant Hypertension market is poised for meaningful growth through 2034, supported by rising prevalence, greater awareness, and continued advancements in therapeutic innovation. While combination pharmacotherapy anchored by CCBs, ACE inhibitors/ARBs, and diuretics remains the standard approach, persistent unmet needs are driving development of novel mechanisms such as aldosterone synthase inhibition, endothelin receptor antagonism, and angiotensinogen-targeted therapies. TRYVIO/JERAYGO has already reshaped the treatment paradigm as the first new antihypertensive class in decades, and promising pipeline candidates such as baxdrostat and lorundrostat have the potential to further transform the landscape. As research progresses and access to innovative therapies expands, the Treatment-Resistant Hypertension market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term cardiovascular risks associated with this condition.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
